EP1658089A4 - Compositions for treating pathologies that necessitate suppression of gastric acid secretion - Google Patents

Compositions for treating pathologies that necessitate suppression of gastric acid secretion

Info

Publication number
EP1658089A4
EP1658089A4 EP04769171A EP04769171A EP1658089A4 EP 1658089 A4 EP1658089 A4 EP 1658089A4 EP 04769171 A EP04769171 A EP 04769171A EP 04769171 A EP04769171 A EP 04769171A EP 1658089 A4 EP1658089 A4 EP 1658089A4
Authority
EP
European Patent Office
Prior art keywords
necessitate
suppression
compositions
gastric acid
acid secretion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04769171A
Other languages
German (de)
French (fr)
Other versions
EP1658089A2 (en
Inventor
Ayelet David
Sabina Glozman
Lada Paul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vecta Ltd
Original Assignee
Vecta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vecta Ltd filed Critical Vecta Ltd
Publication of EP1658089A2 publication Critical patent/EP1658089A2/en
Publication of EP1658089A4 publication Critical patent/EP1658089A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP04769171A 2003-08-27 2004-08-25 Compositions for treating pathologies that necessitate suppression of gastric acid secretion Withdrawn EP1658089A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49793003P 2003-08-27 2003-08-27
US54431804P 2004-02-17 2004-02-17
PCT/IB2004/002745 WO2005020879A2 (en) 2003-08-27 2004-08-25 Compositions for treating pathologies that necessitate suppression of gastric acid secretion

Publications (2)

Publication Number Publication Date
EP1658089A2 EP1658089A2 (en) 2006-05-24
EP1658089A4 true EP1658089A4 (en) 2007-03-14

Family

ID=34278571

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04769171A Withdrawn EP1658089A4 (en) 2003-08-27 2004-08-25 Compositions for treating pathologies that necessitate suppression of gastric acid secretion

Country Status (8)

Country Link
EP (1) EP1658089A4 (en)
JP (1) JP2007503427A (en)
KR (1) KR20060083198A (en)
AU (1) AU2004268446A1 (en)
CA (1) CA2536906A1 (en)
IL (1) IL173944A0 (en)
RU (1) RU2006109357A (en)
WO (1) WO2005020879A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007506730A (en) * 2003-09-24 2007-03-22 ベクタ・リミテッド Oral composition for stimulating gastric acid secretion containing pentagastrin
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
CA2634637A1 (en) * 2005-12-28 2007-07-05 Takeda Pharmaceutical Company Limited Controlled release solid preparation
KR20080081071A (en) * 2005-12-28 2008-09-05 다케다 야쿠힌 고교 가부시키가이샤 Controlled release solid preparation
RU2467747C2 (en) 2006-07-25 2012-11-27 Векта Лтд. Compositions and methods for gastric acid secretion inhibition with using small dicarboxylic acid derivatives in combination with ppi
CN101888828A (en) * 2007-07-27 2010-11-17 蒂宝制药公司 Pulsatile gastric retentive dosage forms
EP4311542A1 (en) * 2022-07-27 2024-01-31 Roquette Freres Floating tab-in-tab dosage forms

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4910021A (en) * 1985-11-29 1990-03-20 R. P. Scherer Corporation Targeted enternal delivery system
JPH04247026A (en) * 1991-01-31 1992-09-03 Teikoku Seiyaku Co Ltd Oral agent disintegrating in lower part of digestive tract
WO2001010405A1 (en) * 1999-08-04 2001-02-15 Ranbaxy Laboratories Limited Hydrodynamically balanced oral drug delivery system
WO2004034957A2 (en) * 2002-10-14 2004-04-29 Vecta Ltd. Methods for treatment of helicobacter pylori-associated disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
JP4377549B2 (en) * 1998-11-17 2009-12-02 ヒッコリー・スペシャルティーズ・インコーポレイテッド Method for coating food products with collagen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4910021A (en) * 1985-11-29 1990-03-20 R. P. Scherer Corporation Targeted enternal delivery system
JPH04247026A (en) * 1991-01-31 1992-09-03 Teikoku Seiyaku Co Ltd Oral agent disintegrating in lower part of digestive tract
WO2001010405A1 (en) * 1999-08-04 2001-02-15 Ranbaxy Laboratories Limited Hydrodynamically balanced oral drug delivery system
WO2004034957A2 (en) * 2002-10-14 2004-04-29 Vecta Ltd. Methods for treatment of helicobacter pylori-associated disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199242, Derwent World Patents Index; AN 1992-343803, XP002414819 *
KATHLEEN PARFITT (ED): "Martindale The Complete Drug Reference", 1999, PHARMACEUTICAL PRESS, LONDON, GB, ISBN: 0 85369 429 X, ISSN: 0263-5364, XP002409837 *

Also Published As

Publication number Publication date
WO2005020879A3 (en) 2005-05-19
WO2005020879A2 (en) 2005-03-10
IL173944A0 (en) 2006-07-05
CA2536906A1 (en) 2005-03-10
RU2006109357A (en) 2007-10-10
AU2004268446A1 (en) 2005-03-10
KR20060083198A (en) 2006-07-20
JP2007503427A (en) 2007-02-22
EP1658089A2 (en) 2006-05-24

Similar Documents

Publication Publication Date Title
IL173944A0 (en) Compositions for treating pathologies that necessitate suppression of gastric acid secretion
PL376178A1 (en) Gastric acid secretion inhibiting composition
IL187236A0 (en) Compositions and methods for inhibiting gastric acid secretion
IL152127A0 (en) Probiotic compositions for the treatment of inflammatory bowel disease
GB0321607D0 (en) Manufacture of pharmaceutical compositions
AU2003205737A1 (en) Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies
GB0221688D0 (en) Compositions for wound treatment
IL175535A0 (en) Compositions for treatment of neurodegenerative diseases
IL173930A0 (en) Pharmaceutical compositions containing forms of r-baclofen
HK1191861A1 (en) Fast acting inhibitor of gastric acid secretion
AU2003248786A8 (en) Compositions comprising panthetine for the treatment of dyslipidemia
AU2003225088A8 (en) Regulation of tnf-alpha
IL179337A0 (en) Pharmaceutical compositions for the treatment of pruritus
PL366653A1 (en) Method for manufacture of polyorganooxosilane compositions
ZA200709852B (en) Spiro-benzimidazoles as inhibitors of gastric acid secretion
EP1765761A4 (en) Novel analogs of 3-o-acetyl-11-keto-beta-boswellic acid
ZA200704775B (en) Compositions for treatment of ear infections
EP1680104A4 (en) Composition for treatment of osteoarthritis containing apigenin as chindroregenerative agent
AU2003225956A8 (en) Apparatus for automatic application of compositions to the skin
GB2355657B (en) Inhibitors Of Gastric Acid Secretion
HUP0303779D0 (en) Pharmaceutical compositions for the treatment of sclerosis multiplex
AU2003244690A8 (en) Compositions for treating digestive functional pathologies
AU2003246098A8 (en) Oxamidination process of carbonyl compounds
EP1663282A4 (en) Oral compositions for the stimulation of gastric acid secretion comprising pentagastrin
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051017

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/08 20060101ALI20070124BHEP

Ipc: A61K 45/06 20060101AFI20070124BHEP

Ipc: A61K 31/4439 20060101ALI20070124BHEP

Ipc: A61P 1/04 20060101ALI20070124BHEP

Ipc: A61K 47/00 20060101ALI20070124BHEP

Ipc: A61K 9/00 20060101ALI20070124BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070207

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DAVID, AYELET

Inventor name: PAUL, LADA

Inventor name: GLOZMAN, SABINA

17Q First examination report despatched

Effective date: 20080208

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080301